Wow, I left for a month and by the time I return someone has referred to me as an “old fart.” It is the first time that has happened to me. I’m not exactly what you’d expect from an old fart.
When I looked over all of these posts, I started see things differently, thinking from a legal rather than scientific perspective. This brought me to this article.
http://www.emcdda.europa.eu/publica...amphetamines-ecstasy/production-precursors_en
It is from 2016, and it claimed that the limiting factor in MDMA mass production is the availability of the precursor. Some people in this thread are way ahead of me, and have already alluded to this point. For me, this article pulled our discussion out to a more massive and global scale, which may impact the way some of you chemists approach the evaluation of different types of MDMA. For example is the chemical in the paragraph below a precursor to 2,3-MDMA found in the Trump pill?
“In 2014, during a survey by the INCB on the use of pre-precursor materials, several governments mentioned a substance called ‘Helional’ (2-methyl-3-(3,4-methylenedioxyphenyl)propanal), a novel precursor for MDA and possibly MDMA. In May 2014, Dutch authorities reported a seizure of 800 litres of Helional at a ‘clandestine warehouse’; more than 500 kg of APAAN was also seized from the same site (INCB, 2015a), indicating that precursor developments continue to evolve and must be carefully and continuously monitored.”
In any case, this is the first time I have read that novel precursors are being used in the production of MDMA. The manufacturers are looking for new ways to make MDMA that don’t rely on traditional substances like sassafrole or …. Piperadole (sp?)/PMK?. Couldn’t this change in synthesis also account for some of the changes we have seen in the way the drug feels? Would it be worthwhile to read more about what types of drugs are being seized in the mass labs busts to get a handle on what might be included in the end product MDMA we see today?
I
didnotice that the article made very little mention of China as a main source of MDMA…so perhaps G-Chem is onto something about the legality of its precursors in china, since the publication date is old and the market has moved on.
@G-Chem: you said that the first phases of the MAPS MDMA trials used “old” MDMA pills. How did you know this? (And I mean this with complete curiosity so that I can find that kind of information when I read). Also, I would guess that pharmaceutical company (I’m not sure if this is Merck or Dole at this point?) would have to be involved at some point in the study – someone with a patent has to make the supply once the demand is created by a successful study.
Lastly, could you theoretically test a pill for a trace amount of a known precursor – say saffrole - and then you would know that you were likely to have a “good” pill? Ie, would every pill have some trace amount of the initial precursor in it? Maybe the smaller labs with better product use higher quality , identifiable precursors in them?